Clinical studies recruiting near Long Branch

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Merck Sharp & Dohme LLC · NCT06077760 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Monmouth Medical Center · NRG Oncology · NCT05174169 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Monmouth Medical Center · National Cancer Institute (NCI) · NCT04269902 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · Eli Lilly and Company · NCT06119581 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Monmouth Medical Center · National Cancer Institute (NCI) · NCT05256225 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · NRG Oncology · NCT04852887 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Monmouth Medical Center · National Cancer Institute (NCI) · NCT06058377 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Monmouth Medical Center · National Cancer Institute (NCI) · NCT05987241 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Tr
Phase 3 · Merck Sharp & Dohme LLC · NCT06312176 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · Monmouth Medical Center · National Cancer Institute (NCI) · NCT05564377 Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Mirati Therapeutics Inc. · NCT04613596 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · Monmouth Medical Center · ECOG-ACRIN Cancer Research Group · NCT02734537 Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Phase 1/Phase 2 · Merck Sharp & Dohme LLC · NCT06596694 S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · SWOG Cancer Research Network · NCT03723928 Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT06475989 BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Phase 3 · Pfizer · NCT07160244 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · Merck Sharp & Dohme LLC · NCT06966700 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · National Cancer Institute (NCI) · NCT03866382 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT03937635 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Pr
Phase 3 · Merck Sharp & Dohme LLC · NCT06717347 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L
Phase 2 · SWOG Cancer Research Network · NCT05642572 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · Monmouth Medical Center · National Cancer Institute (NCI) · NCT04181060 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After
Phase 3 · Monmouth Medical Center · Alliance for Clinical Trials in Oncology · NCT05812807 A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Phase 1/Phase 2 · Merck Sharp & Dohme LLC · NCT06428409 MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Stryker Instruments · NCT03072927 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · Celgene · NCT06764485 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Ute
Phase 3 · BioNTech SE · NCT06340568 A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensiti
Phase 3 · Eli Lilly and Company · NCT07213804 Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Me
Phase 3 · SWOG Cancer Research Network · NCT05561387 Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · National Cancer Institute (NCI) · NCT03739814

Look up another city

Look up another condition